| Mact Medical Jackson | |
|
12140/12150 New York Ranch Rd Jackson CA 95642-9407 | |
| (209) 257-2400 | |
| (209) 257-2403 |
| Full Name | Mact Medical Jackson |
|---|---|
| Speciality | Clinic/Center |
| Location | 12140/12150 New York Ranch Rd, Jackson, California |
| Authorized Official Name and Position | John Alexander (EXECUTIVE DIRECTOR) |
| Authorized Official Contact | 2097546262 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Mact Medical Jackson Po Box 939 Angels Camp CA 95222-0939 Ph: (209) 754-6262 | Mact Medical Jackson 12140/12150 New York Ranch Rd Jackson CA 95642-9407 Ph: (209) 257-2400 |
| NPI Number | 1295727287 |
|---|---|
| Provider Enumeration Date | 08/17/2005 |
| Last Update Date | 11/17/2022 |
| Medicare PECOS PAC ID | 8325936974 |
|---|---|
| Medicare Enrollment ID | O20170324000662 |
News Archive
Case Western Reserve University School of Dental Medicine announced a new program called Family First in which they will adopt nine families and care for multiple generations in a family unit.
BioMimetic Therapeutics, Inc. today reported its financial results as of and for the three and six months ended June 30, 2010. For the three months ended June 30, 2010, the Company reported a net loss of $7.7 million, or $0.35 per diluted share, compared to a net loss of $6.3 million, or $0.32 per diluted share, for the same period in 2009. For the six months ended June 30, 2010, the Company reported a net loss of $16.2 million, or $0.73 per diluted share, compared to a net loss of $14.3 million, or $0.75 per diluted share, for the same period in 2009.
Minnesota hospitals and health systems have prevented more than 12,000 patients from being harmed and saved more than $93 million as a result of a reduction in hospital-acquired conditions from 2010-13. Nationwide, hospitals prevented 1.3 million patient harms and saved more than $12 billion in health spending, according to a report issued today by the U.S. Department of Health and Human Services.
Geron Corporation today announced the enrollment of the first patient in the company's clinical trial of human embryonic stem cell (hESC)-derived oligodendrocyte progenitor cells, GRNOPC1. The primary objective of this Phase I study is to assess the safety and tolerability of GRNOPC1 in patients with "complete" American Spinal Injury Association (ASIA) Impairment Scale grade A thoracic spinal cord injuries. Participants in the study must be newly injured and receive GRNOPC1 within 14 days of the injury.
› Verified 8 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295727287 | NPI | - | NPPES |
| THP70776F | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261Q00000X | Clinic/center | (* (Not Available)) | Primary |
| 261QC1500X | Clinic/center - Community Health | (* (Not Available)) | Secondary |
News Archive
Case Western Reserve University School of Dental Medicine announced a new program called Family First in which they will adopt nine families and care for multiple generations in a family unit.
BioMimetic Therapeutics, Inc. today reported its financial results as of and for the three and six months ended June 30, 2010. For the three months ended June 30, 2010, the Company reported a net loss of $7.7 million, or $0.35 per diluted share, compared to a net loss of $6.3 million, or $0.32 per diluted share, for the same period in 2009. For the six months ended June 30, 2010, the Company reported a net loss of $16.2 million, or $0.73 per diluted share, compared to a net loss of $14.3 million, or $0.75 per diluted share, for the same period in 2009.
Minnesota hospitals and health systems have prevented more than 12,000 patients from being harmed and saved more than $93 million as a result of a reduction in hospital-acquired conditions from 2010-13. Nationwide, hospitals prevented 1.3 million patient harms and saved more than $12 billion in health spending, according to a report issued today by the U.S. Department of Health and Human Services.
Geron Corporation today announced the enrollment of the first patient in the company's clinical trial of human embryonic stem cell (hESC)-derived oligodendrocyte progenitor cells, GRNOPC1. The primary objective of this Phase I study is to assess the safety and tolerability of GRNOPC1 in patients with "complete" American Spinal Injury Association (ASIA) Impairment Scale grade A thoracic spinal cord injuries. Participants in the study must be newly injured and receive GRNOPC1 within 14 days of the injury.
› Verified 8 days ago
Helene Malabed, Do & Terrence C. Turpen, Pa-c Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 601 Court St. Suite 210, Jackson, CA 95642 Phone: 209-223-7784 Fax: 209-223-7783 | |
Jackson Rancheria Medical Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 12222 New York Ranch Rd, Jackson, CA 95642 Phone: 209-223-8428 Fax: 209-223-8429 | |
Amador Family Physicians Medical Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 605 New York Ranch Rd, Jackson, CA 95642 Phone: 209-223-2030 Fax: 209-223-2303 | |
Thomas Bowhay, M.d. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1245 Jackson Gate Rd, Jackson, CA 95642 Phone: 209-223-7040 Fax: 209-223-7606 | |
Anant Lodhia Md Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 601 Court St Ste 210, Jackson, CA 95642 Phone: 209-223-7784 Fax: 209-223-7783 | |
Hospitalist Medicine Physicians Of California - Jackson, Pc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 200 Mission Blvd, Jackson, CA 95642 Phone: 209-223-7500 |